Company Profile
Kura Oncology Stock Price, News & Analysis
Company overview
Business overview
Kura Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Kura Oncology is followed within the oncology universe where readouts and regulatory timing often dominate the stock.
Business Model Characteristics
Kura Oncology follows a pipeline-and-commercial model where investors track trial execution, launch cadence, and the pace at which oncology data can be turned into durable product value.
Position Within the Biotechnology Landscape
Compared with larger diversified peers, Kura Oncology sits in a high-catalyst corner of the biotech landscape, where oncology updates can reprice the stock quickly.
Why the stock is moving
KURA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Kura Oncology's catalysts are ziftomenib in NPM1-mutant AML and the broader menin-inhibitor program, where the next clinical update can materially change the market's view of the franchise. Investors will also watch whether the company can keep advancing its combination strategy in hematology without losing momentum to the next data cycle.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Source: Kura Oncology
- 02
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Source: Kura Oncology
- 03
- 04
- 05
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Source: Kura Oncology
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.